George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
buy
buy
In a year of transition for the Company, there have been many positive changes. Relationships with our distribution partners have been strengthened and revenues have returned to growth on solid foundations. Manufacturing and operating costs have been reduced, and working capital has been brought into line with the current needs of what is now a cash generative business. "With these changes delivered and a solid platform secured for future growth, we now have a Board and management structure intended to drive the future direction and development of the business. "There has been further improvement in performance in the current financial year to date. Although there remain some challenges in building on the improvements delivered in 2015, we look forward with renewed confidence."
The use of 3mm instrumentation significantly reduces pain scores compared to conventional laparoscopy, which can in turn reduce the analgesia needed.
3mm incisions heal leaving significantly smaller scars than in traditional laparoscopy, not only immediately after the operation but also at 6-month follow up. Pigmentation also decreases as the size of the scar becomes smaller.
3mm incisions can negate the need for port site suturing at the end of procedures, which saves the patients from the discomfort of stitch removal.
Replacing 5mm with 3mm ports reduces tissue displacement from each cannula by at least 57%. By reducing the level of local tissue damage, the use of the LAP³ procedure kit for a 4-port laparoscopic cholecystectomy allows maximum visibility of Calotís triangle while still achieving a 13% reduction in the combined tissue displacement compared to a 3-port technique using 5mm ports.
The use of smaller instrumentation for laparoscopic cholecystectomy has been associated with lower hospital costs, likely to be due to a reduction in patient pain, trauma and adverse events thus increasing the likelihood of a same-day hospital discharge.
Lap3 Procedure Kit The LAP³ kit overcomes many previous obstacles to 3mm surgery, due to the availability of the world's first and only 3mm clip applier. Each single-use element required is included within the kit. The reusable components to accompany each single-use device must be purchased separately. This combination of reusable and single-use products create a fully Resposable® solution. The LAP³ kit is ideal for application in laparoscopic cholecystectomy, appendectomy and varicocelectomy, along with many more laparoscopic procedures.
can do better ..need few buy
Sold out of SUN a few years ago at 12p for a modest profit but bought back in again on the way down. Current average 2.9p. Following yesterday's solid results and recent announcements, I would have thought we would see a bigger rise than this. I have a small part time job in a small local hospital and a colleague in receipts and deliveries says they get loads of SI products in for the theatres. Think this is way oversold but market still nervous in view of previous problems. Will be keeping this one in the bottom drawer and happy to wait a few years for hopefully very decent returns.
Surgical Innovations (LON:SUN) saw losses come down and revenues rise as the group expanded further into the US. Following reportedly severe challenges breaking the US market, revenues across ten active states almost doubled to £1.54mln a year. The group entered into a distribution agreement in February to generate sales in US territories not yet covered. The core strategy of the group remained the sale of laparoscopic, or keyhole, surgery products and the US is the largest market in the world for laparoscopic surgery. For the year ended 31 December, revenue stood at £5.47mln, compared to £4.03mln in the same period last year, an increase of 36%. Operating losses in 2015 were £1.98mln down from £9.78mln in 2014, while the loss after tax was £2.03mln, compared to a loss of £9.46mln. In 2014 the group was hit by significant debt and restructuring expenses. However gross margin for the year was down to 14% due to inventory reduction. More than a third of total sales were sourced from existing stock, which adversely affected manufacturing overhead recovery, it reported. “There remain some challenges in building on the improvements delivered in 2015, not least in sustaining revenue growth to consistently generate positive returns,” said executive chairman Nigel Rogers. “We believe that we have the opportunities and resources required to achieve this, and look forward with renewed confidence.”
At least one buy blue
Lonely
Showing as a sell
1.50 ....was buy & sell ...now going higher ....1.59 to buy
Surgical Innovations has booked a reduced FY pretax loss of GBP2.1m, from a year-ago loss of GBP9.8m, as revenue rose to GBP5.5m, from GBP4.0m. Executive chairman Nigel Rogers said: "In a year of transition for the Company, there have been many positive changes. Relationships with our distribution partners have been strengthened and revenues have returned to growth on solid foundations. "Manufacturing and operating costs have been reduced, and working capital has been brought into line with the current needs of what is now a cash generative business. "With these changes delivered and a solid platform secured for future growth, we now have a Board and management structure intended to drive the future direction and development of the business. "There has been further improvement in performance in the current financial year to date. Although there remain some challenges in building on the improvements delivered in 2015, we look forward with renewed confidence." HIGHLIGHTS: · Gross margin improvement in second half of the year (2015: 14.0%, H1: 8.4%, H2: 19.2%) · Adjusted EBITDA of £0.24m (2014: Adjusted EBITDA loss of £0.05m) · Inventory reduction programme well advanced (2015: £1.92m, 2014: £4.30m) · Net cash generated from operations of £1.57m (2014: £0.69m net cash consumed) · Net indebtedness reduced to £2.26m (2014: £3.33m) · New Board of directors and key management team in place · New sales channels and products coming on stream in 2016 At 9:33am: (LON:SUN) Surgical Innovations Group PLC share price was +0.15p at 1.63p
New sales channels and products coming on stream in 2016
oversold
New Board of directors and key management team in place
looking good
16 March 2016 Surgical Innovations Group plc ("SI", "the Company", or the "Group") Final results for year ended 31 December 2015 Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical technology for minimally invasive surgery, reports significantly improved financial results for the year ended 31 December 2015. Revenues and margins continue to show encouraging progress, whilst significant reductions in net operating costs, working capital and net indebtedness have been achieved. Highlights: · Revenues up 36% to £5.47m (2014: £4.03m) · Gross margin improvement in second half of the year (2015: 14.0%, H1: 8.4%, H2: 19.2%) · Adjusted EBITDA of £0.24m (2014: Adjusted EBITDA loss of £0.05m) · Inventory reduction programme well advanced (2015: £1.92m, 2014: £4.30m) · Net cash generated from operations of £1.57m (2014: £0.69m net cash consumed) · Net indebtedness reduced to £2.26m (2014: £3.33m) · New Board of directors and key management team in place · New sales channels and products coming on stream in 2016 Executive Chairman, Nigel Rogers, said: "In a year of transition for the Company, there have been many positive changes. Relationships with our distribution partners have been strengthened and revenues have returned to growth on solid foundations. Manufacturing and operating costs have been reduced, and working capital has been brought into line with the current needs of what is now a cash generative business. "With these changes delivered and a solid platform secured for future growth, we now have a Board and management structure intended to drive the future direction and development of the business. "There has been further improvement in performance in the current financial year to date. Although there remain some challenges in building on the improvements delivered in 2015, we look forward with renewed confidence."
Still within a bear trend and up to now fundamentals are a bit shakey but things do look like things are turning a corner and from a TA view its very close to breakout and start a new trend north. This is whats catching my eye along with possible news. Still watching and waiting for SUNs fate
All I did was let Melanie know we had high expectations. Did it have any effect? I don't know and if no longer matters, all the best, Paul.
Let me know if you want to drop me a message off the boards. Would love to hear your views. Im eyeing up a 1-1.20p entry and possible build up a stake in that range. Wanting to build up a stake before results and bullish news